Twinvest...in answer to yr question....I think I have already outlined that in previous posts but to clarify,,,,
Quite simply..they diluted their holding because .... - they are only wanting to focus on brevagen - they made a corporate decision to leave immunaid on the back burner - they did not want to put money into immunaid , only brevagen - they prefered to reduce their stake and have all loans repaid as a result of round 1 immunaid capital raise - the other investors of immunaid wanted them (gtg) to dilute so other investors could get on board - they (gtg) determined that the repayment of approx 400-500k by immunaid and the increased value of their remaining 46% was worth more than waiting for immunaid to take off, but that couldn't happen if they didn't want to spend further effort or funds to do so - they (gtg) now get a free ride on Immunaids successes moving forward and the increase in value that will occur from rnd 2 capital raise and opportunities that will now become apparent by immunaid pushing forward on it's own and determining it's own destiny.....
Hope this helps
Ps....re fda equeries etc etc,,,brevagen is not a drug, It's a test....immunaid is not a test.....it's a method of controlled or timed therapy of treatments, using existing methods, but at specific times when the body's own immune system can fight the decease, iand possibly eradicate it altogether.....
-
GTG Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
